Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shah Ali Akbar Ashrafi has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Shifting Geographical Transmission Patterns: Characterizing the 2023 Fatal Dengue Outbreak in Bangladesh

    by Mohammad Nayeem Hasan, Mahbubur Rahman, Meraj Uddin, Shah Ali Akbar Ashrafi, Kazi Mizanur Rahman, Kishor Kumar Paul, Mohammad Ferdous Rahman Sarker, Farhana Haque, Avinash Sharma, Danai Papakonstantinou, et al.

    In 2023, Bangladesh experienced its largest and deadliest outbreak of Dengue virus (DENV), reporting the highest-ever recorded annual cases and deaths. We aimed to characterize the geographical transmission of the DENV in Bangladesh. From 1 Jan – 31 Dec 2023, we extracted and analyzed daily data on dengue cases and deaths from the national Management Information System (MIS). We performed a generalized linear mixed model to identify the associations between division-wise daily dengue counts and various geographical and meteorological covariates. The number of Dengue cases reported in 2023 was 1.3 times higher than the total number recorded in the past 23 years (321,179 vs. 244,246), with twice as many deaths than the total fatalities recorded in the past 23 years (1705 vs. 849). Of the 1705 deaths in 2023, 67.4% (n=1015) expired within one day after hospital admission. The divisions southern to Dhaka had a higher dengue incidence/1000 population (2.30 vs. 0.50, p<0,0.01), and higher mean annual temperatures (27.46 vs. 26.54 °C) than the northern divisions. The average daily temperature (IRR: 1.13, 95% CI: 1.11-1.14), urban and rural population ratio of the divisions (IRR: 1.04, 95% CI: 1.03-1.04), showed a positive, and rainfall (IRR: 0.99, 95% CI: 0.98-0.99) showed a negative association with dengue cases in each division. We observed a major geographical shift of Dengue cases from the capital city Dhaka to different districts of Bangladesh with a higher incidence of dengue in the southern division of Bangladesh, influenced by temperature and urbanization.


  • Open Access

    Bangladesh's 2023 Dengue outbreak – age/gender-related disparity in morbidity and mortality and geographic variability of epidemic burdens

    by Najmul Haider, Asaduzzaman, Mohammad Nayeem Hasan, Mahbubur Rahman, Ahmed Raihan Sharif, Shah Ali Akbar Ashrafi, Shui Shan Lee, Alimuddin Zumla


  • Open Access

    Measuring the Effectiveness of COVID-19 Vaccines Used during a Surge of the Delta Variant of SARS-CoV-2 in Bangladesh: A Test-Negative Design Evaluation

    by Farhana Khanam, Taufiqul Islam, Faisal Ahmmed, Shams Uddin Ahmed, Ismail Hossen, MdNazmul Hasan Rajib, Shahinur Haque, Prasanta Kumar Biswas, Imam Tauheed, K Zaman, et al.

    Background: From May to December 2021, Bangladesh experienced a major surge in the Delta variant of SARS-CoV-2. The earlier rollout of several vaccines offered the opportunity to evaluate vaccine effectiveness against this variant. Methods: A prospective, test-negative case-control study was conducted in five large hospitals in Dhaka between September and December 2021. The subjects were patients of at least 18 years of age who presented themselves for care, suffering COVID-like symptoms of less than 10 days’ duration. The cases had PCR-confirmed infections with SARS-CoV-2, and up to 4 PCR test-negative controls were matched to each case, according to hospital, date of presentation, and age. Vaccine protection was assessed as being the association between the receipt of a complete course of vaccine and the occurrence of SARS-CoV-2 disease, with symptoms beginning at least 14 days after the final vaccine dose. Results: In total, 313 cases were matched to 1196 controls. The genotyping of case isolates revealed 99.6% to be the Delta variant. Receipt of any vaccine was associated with 12% (95% CI: −21 to 37, p = 0.423) protection against all episodes of SARS-CoV-2. Among the three vaccines for which protection was evaluable (Moderna (mRNA-1273); Sinopharm (Vero Cell-Inactivated); Serum Institute of India (ChAdOx1 nCoV-19)), only the Moderna vaccine was associated with significant protection (64%; 95% CI: 10 to 86, p = 0.029). Protection by the receipt of any vaccine against severe disease was 85% (95% CI: 27 to 97, p = 0.019), with protection estimates of 75% to 100% for the three vaccines. Conclusions: Vaccine protection against COVID-19 disease of any severity caused by the Delta variant was modest in magnitude and significant for only one of the three evaluable vaccines. In contrast, protection against severe disease was high in magnitude and consistent for all three vaccines. Because our findings are not in complete accord with evaluations of the same vaccines in more affluent settings, our study underscores the need for country-level COVID-19 vaccine evaluations in developing countries.


  • Open Access

    Automated verbal autopsy: from research to routine use in civil registration and vital statistics systems

    by Riley H. Hazard, Mahesh P. K. Buddhika, John D. Hart, Hafizur R. Chowdhury, Sonja Firth, Rohina Joshi, Ferchito Avelino, Agnes Segarra, Deborah Carmina Sarmiento, Abdul Kalam Azad, et al.

    Background: The majority of low- and middle-income countries (LMICs) do not have adequate civil registration and vital statistics (CRVS) systems to properly support health policy formulation. Verbal autopsy (VA), long used in research, can provide useful information on the cause of death (COD) in populations where physicians are not available to complete medical certificates of COD. Here, we report on the application of the SmartVA tool for the collection and analysis of data in several countries as part of routine CRVS activities. Methods: Data from VA interviews conducted in 4 of 12 countries supported by the Bloomberg Philanthropies Data for Health (D4H) Initiative, and at different stages of health statistical development, were analysed and assessed for plausibility: Myanmar, Papua New Guinea (PNG), Bangladesh and the Philippines. Analyses by age- and cause-specific mortality fractions were compared to the Global Burden of Disease (GBD) study data by country. VA interviews were analysed using SmartVA-Analyze-automated software that was designed for use in CRVS systems. The method in the Philippines differed from the other sites in that the VA output was used as a decision support tool for health officers. Results: Country strategies for VA implementation are described in detail. Comparisons between VA data and country GBD estimates by age and cause revealed generally similar patterns and distributions. The main discrepancy was higher infectious disease mortality and lower non-communicable disease mortality at the PNG VA sites, compared to the GBD country models, which critical appraisal suggests may highlight real differences rather than implausible VA results. Conclusion: Automated VA is the only feasible method for generating COD data for many populations. The results of implementation in four countries, reported here under the D4H Initiative, confirm that these methods are acceptable for wide-scale implementation and can produce reliable COD information on community deaths for which little was previously known.